Literature DB >> 33485463

Immune checkpoint inhibitors in mesothelioma: a turning point.

Giovanni Luca Ceresoli1, Giulia Pasello2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33485463     DOI： 10.1016/S0140-6736(21)00147-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations.

Authors:  Laura Mannarino; Federica Mirimao; Monica Lupi; Maurizio D'Incalci; Nicolò Panini; Lara Paracchini; Sergio Marchini; Luca Beltrame; Rosy Amodeo; Federica Grosso; Roberta Libener; Irene De Simone; Giovanni L Ceresoli; Paolo A Zucali
Journal:  Cell Death Dis       Date:  2022-07-15       Impact factor: 9.685

Review 2.  Role of the tumor immune microenvironment in tumor immunotherapy.

Authors:  Changsheng Zhou; Qianqian Liu; Yi Xiang; Xin Gou; Wengang Li
Journal:  Oncol Lett       Date:  2021-12-20       Impact factor: 2.967

3.  Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.

Authors:  Zhuo-Miao Ye; Zi-Qing Tang; Zhe Xu; Qin Zhou; Huan Li
Journal:  Front Public Health       Date:  2022-07-22

4.  Prediction of Two Molecular Subtypes of Gastric Cancer Based on Immune Signature.

Authors:  Dan Wu; Mengyao Feng; Hongru Shen; Xilin Shen; Jiani Hu; Jilei Liu; Yichen Yang; Yang Li; Meng Yang; Wei Wang; Qiang Zhang; Fangfang Song; Ben Liu; Kexin Chen; Xiangchun Li
Journal:  Front Genet       Date:  2022-01-17       Impact factor: 4.599

Review 5.  [Research Progress of Immune Checkpoint Inhibitors 
in Malignant Pleural Mesothelioma].

Authors:  Yaru Huang; Qingwei Meng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.